|Articles|February 15, 2002
- BioPharm International-02-01-2002
- Volume 15
- Issue 2
Inside Washington: Costs and Controls Challenge Manufacturers
Author(s)Jill Wechsler
By Jill Wechsler, pp. 52-56. More curbs on reimbursement for expensive, cutting-edge therapies may shape R&D programs and industry growth
Advertisement
Articles in this issue
over 23 years ago
Outsourcing Outlook: Reaping the Benefits of E-Procurementover 23 years ago
The Immunogenicity of Therapeutic Proteinsover 23 years ago
21 CFR Part 11: (Un)Expected Added ValueNewsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Analyzing the Safety and Scope of Next-Generation Gene Editing Platforms
2
How Rentschler Biopharma’s New Platforms Aim to Accelerate Biologics Development in Asia
3
Why Flexibility and Commercial Viability Must Be Built-in Early for Scaling CGTs
4
Selecting the Right Drug Delivery Formulations to Enhance Patient-Centric Care
5
